Trade name: Erlonat
Erlonat is the trade name for the generic drug name Erlotinib. In some cases, health care professionals may use the trade name Tarceva when referring to the generic drug name Erlotinib.
Drug type: Erlotinib is a targeted therapy. Erlotinib is classified as a epidermal growth factor receptor (EGFR) inhibitor – protein-tyrosine kinase inhibitor. (For more detail, see “How this drug works,” below.)
What Erlotinib is used for:
Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
How Erlotinib is given:
Erlotinib is given in tablet form to be taken by mouth at least one hour before or two hours after eating. The tablets are supplied in 25mg, 100mg and 150mg strengths.
The amount of erlotinib that you will receive depends on many factors, including your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.
Side effects of Erlotinib:
Important things to remember about the side effects of erlotinib:
Most people do not experience all of the side effects listed.
Side effects are often predictable in terms of their onset and duration.
Side effects are almost always reversible and will go away after treatment is complete.
There are many options to help minimize or prevent side effects.
The following side effects are common (occurring in greater than 30%) for patients taking Erlotinib:
Shortness of breath
Nausea and vomiting
These side effects are less common side effects (occurring in about 10-29%) of patients receiving Erlotinib: